RGNX
Price
$8.19
Change
-$0.32 (-3.76%)
Updated
Aug 1 closing price
Capitalization
412.68M
95 days until earnings call
SYRE
Price
$16.26
Change
-$0.71 (-4.18%)
Updated
Aug 1 closing price
Capitalization
981.35M
96 days until earnings call
Interact to see
Advertisement

RGNX vs SYRE

Header iconRGNX vs SYRE Comparison
Open Charts RGNX vs SYREBanner chart's image
REGENXBIO
Price$8.19
Change-$0.32 (-3.76%)
Volume$539.93K
Capitalization412.68M
Spyre Therapeutics
Price$16.26
Change-$0.71 (-4.18%)
Volume$551.67K
Capitalization981.35M
RGNX vs SYRE Comparison Chart in %
Loading...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
RGNX vs. SYRE commentary
Aug 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RGNX is a Hold and SYRE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 02, 2025
Stock price -- (RGNX: $8.19 vs. SYRE: $16.26)
Brand notoriety: RGNX and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RGNX: 64% vs. SYRE: 93%
Market capitalization -- RGNX: $412.68M vs. SYRE: $981.35M
RGNX [@Biotechnology] is valued at $412.68M. SYRE’s [@Biotechnology] market capitalization is $981.35M. The market cap for tickers in the [@Biotechnology] industry ranges from $213.98B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RGNX’s FA Score shows that 1 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • RGNX’s FA Score: 1 green, 4 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, RGNX is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RGNX’s TA Score shows that 2 TA indicator(s) are bullish while SYRE’s TA Score has 5 bullish TA indicator(s).

  • RGNX’s TA Score: 2 bullish, 6 bearish.
  • SYRE’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, SYRE is a better buy in the short-term than RGNX.

Price Growth

RGNX (@Biotechnology) experienced а -8.59% price change this week, while SYRE (@Biotechnology) price change was -8.60% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.14%. For the same industry, the average monthly price growth was +15.55%, and the average quarterly price growth was +36.18%.

Reported Earning Dates

RGNX is expected to report earnings on Nov 05, 2025.

SYRE is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+0.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SYRE($981M) has a higher market cap than RGNX($413M). RGNX YTD gains are higher at: 5.951 vs. SYRE (-30.155). RGNX has higher annual earnings (EBITDA): -122.44M vs. SYRE (-214.36M). SYRE has more cash in the bank: 565M vs. RGNX (268M). SYRE has less debt than RGNX: SYRE (0) vs RGNX (79.8M). RGNX has higher revenues than SYRE: RGNX (157M) vs SYRE (0).
RGNXSYRERGNX / SYRE
Capitalization413M981M42%
EBITDA-122.44M-214.36M57%
Gain YTD5.951-30.155-20%
P/E RatioN/A1.72-
Revenue157M0-
Total Cash268M565M47%
Total Debt79.8M0-
FUNDAMENTALS RATINGS
RGNX vs SYRE: Fundamental Ratings
RGNX
SYRE
OUTLOOK RATING
1..100
1210
VALUATION
overvalued / fair valued / undervalued
1..100
72
Overvalued
74
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9697
PRICE GROWTH RATING
1..100
6155
P/E GROWTH RATING
1..100
2181
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RGNX's Valuation (72) in the Biotechnology industry is in the same range as SYRE (74) in the Pharmaceuticals Major industry. This means that RGNX’s stock grew similarly to SYRE’s over the last 12 months.

RGNX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as SYRE (100) in the Pharmaceuticals Major industry. This means that RGNX’s stock grew similarly to SYRE’s over the last 12 months.

RGNX's SMR Rating (96) in the Biotechnology industry is in the same range as SYRE (97) in the Pharmaceuticals Major industry. This means that RGNX’s stock grew similarly to SYRE’s over the last 12 months.

SYRE's Price Growth Rating (55) in the Pharmaceuticals Major industry is in the same range as RGNX (61) in the Biotechnology industry. This means that SYRE’s stock grew similarly to RGNX’s over the last 12 months.

RGNX's P/E Growth Rating (21) in the Biotechnology industry is somewhat better than the same rating for SYRE (81) in the Pharmaceuticals Major industry. This means that RGNX’s stock grew somewhat faster than SYRE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RGNXSYRE
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
88%
Momentum
ODDS (%)
Bearish Trend 3 days ago
79%
Bullish Trend 3 days ago
83%
MACD
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
84%
Advances
ODDS (%)
Bullish Trend 10 days ago
76%
Bullish Trend 11 days ago
85%
Declines
ODDS (%)
Bearish Trend 5 days ago
84%
Bearish Trend 5 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
83%
Bullish Trend 3 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GTDCX35.88N/A
N/A
Invesco EQV Emerging Markets All Cap C
LAMAX24.37N/A
N/A
Lord Abbett Dividend Growth A
GCSAX25.96N/A
N/A
Goldman Sachs Small Cap Eq Insghts A
APTTF0.07N/A
N/A
Asian Pay Television Trust
MCUJF0.94N/A
N/A
Medicure Inc.

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with IDYA. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
-4.18%
IDYA - SYRE
60%
Loosely correlated
-0.33%
CGON - SYRE
58%
Loosely correlated
-1.42%
BEAM - SYRE
58%
Loosely correlated
-4.46%
XNCR - SYRE
57%
Loosely correlated
-4.09%
CRNX - SYRE
54%
Loosely correlated
-2.62%
More